Celltrion announced on October 17, 2025, that the U.S. FDA has approved label expansions for YUFLYMA® (adalimumab-aaty) and its unbranded counterpart, extending treatment to adolescent hidradenitis suppurativa (HS) in patients aged 12 and older and pediatric uveitis (UV) in children aged 2 and older. Previously approved for adult HS and UV, these new indications mark a significant advancement in managing chronic immune-mediated diseases in younger populations.
Innovent Biologics, a leading Chinese biopharmaceutical firm focused on oncology, metabolic, and autoimmune therapies, announced positive topline results from its fourth phase 3 trial, DREAMS-3 (NCT06184568), evaluating mazdutide (Xinermei®)—a once-weekly subcutaneous GLP-1 and glucagon (GCG) dual receptor agonist licensed exclusively from Eli Lilly for development in China. Originally discovered by Lilly, mazdutide targets both receptors to enhance glycemic control and promote significant weight loss, addressing the intertwined epidemics of T2D and obesity in China, where over 140 million adults live with T2D and obesity rates exceed 16%.
On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved Lynkuet™ (elinzanetant), developed by Bayer, as the first dual neurokinin (NK) targeted therapy—a combined NK1 and NK3 receptor antagonist—for the treatment of moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, due to menopause. This non-hormonal, once-daily oral therapy addresses a major unmet need in menopausal care, where VMS affect daily functioning, sleep, and quality of life and are a primary reason women seek medical intervention.
The Phase 2 DAHLIAS study (NCT04968912), a multicenter, randomized, placebo-controlled, double-blind trial, evaluated nipocalimab—an investigational monoclonal antibody targeting the neonatal Fc receptor (FcRn)—in adults aged 18–75 with moderate-to-severe primary Sjögren’s disease (SjD) seropositive for anti-Ro60 and/or anti-Ro52 IgG autoantibodies. A total of 163 participants were randomized 1:1:1 to receive intravenous nipocalimab 5 mg/kg, 15 mg/kg, or placebo every 2 weeks through Week 22, alongside standard-of-care therapy. The primary endpoint was the change from baseline in the Clinical EULAR Sjögren’s Syndrome Disease Activity Index (ClinESSDAI) score at Week 24, a composite measure assessing 11 systemic domains including constitutional symptoms, lymphadenopathy, glandular swelling, articular, cutaneous, respiratory, renal, muscular, peripheral/central nervous system, and hematological involvement.
The extended follow-up of the DANISH trial, published in the Journal of the American College of Cardiology on October 22, 2025, provides critical long-term insights into the role of primary prevention implantable cardioverter-defibrillators (ICDs) in patients with nonischemic heart failure with reduced ejection fraction (HFrEF). Originally published in 2016 with a median follow-up of 5.6 years, the trial showed no significant reduction in all-cause mortality with ICDs. This new analysis extends median follow-up to 13.2 years (IQR 11.6–14.6 years), tracking 1,116 randomized patients until death or January 31, 2024.
